Robert Purvis, MD
Dermatology · Myrtle Beach, SCNPI 1154373827
Payments from drug & device makers
Across 502 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Johnson & Johnson$1K
- Incyte Corporation$1K
- Pfizer$972
- plus $7K from 31 others
What the payments were for
- Food & beverage$14,65995%
- Education$7025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,970 |
| Sun Pharmaceutical Industries Inc. | 56 | $1,719 |
| Regeneron Healthcare Solutions, Inc. | 39 | $1,377 |
| Johnson & Johnson | 67 | $1,319 |
| Incyte Corporation | 23 | $1,097 |
| Pfizer | 39 | $972 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 28 | $769 |
| Janssen Scientific Affairs, LLC | 5 | $643 |
| Arcutis Biotherapeutics, Inc. | 11 | $587 |
| Sanofi | 9 | $524 |
| Novartis | 20 | $458 |
| Lilly USA, LLC | 22 | $444 |
| LEO Pharma Inc. | 11 | $403 |
| Sanofi-aventis U.S. LLC | 4 | $385 |
| Amgen | 11 | $322 |
| Bristol Myers Squibb | 7 | $315 |
| Almirall LLC | 4 | $226 |
| E.r. Squibb & Sons, L.L.C. | 5 | $213 |
| Organogenesis Inc. | 5 | $186 |
| UCB, Inc. | 8 | $181 |
| Boehringer Ingelheim | 2 | $167 |
| Galderma Laboratories, L.p. | 12 | $157 |
| Genentech USA, Inc. | 6 | $121 |
| Dermira, Inc. | 2 | $116 |
| Biofrontera Inc. | 5 | $110 |
| Dermavant Sciences, Inc. | 2 | $103 |
| Kerecis Limited | 3 | $99 |
| Caris MPI, Inc. | 1 | $80 |
| Verrica Pharmaceuticals Inc. | 2 | $80 |
| Journey Medical Corporation | 3 | $70 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $24 |
| Biowound Solutions, Inc. | 1 | $23 |
| Strata Skin Sciences, Inc. | 2 | $21 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $12 |
| Misonix Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,361 in reported general payments places this provider in the 85th percentile of 203 dermatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 25 | $250,251 |
| Dupixent PenDupilumab | 43 | $185,871 |
| ErivedgeVismodegib | 11 | $154,034 |
| OtezlaApremilast | 24 | $114,762 |
| Dupixent SyringeDupilumab | 17 | $114,335 |
| RinvoqUpadacitinib | 11 | $69,872 |
| JubliaEfinaconazole | 35 | $33,299 |
| ZoryveRoflumilast | 32 | $26,425 |
| KlisyriTirbanibulin | 15 | $16,874 |
| Ketoconazole | 367 | $5,182 |
| Gentamicin Sulfate | 154 | $5,131 |
| Acitretin | 11 | $3,195 |
| Fluocinonide | 87 | $3,064 |
| Doxycycline Hyclate | 109 | $2,186 |
| Mupirocin | 224 | $1,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Erivedge | $121 | $154,03411 claims |
| AmgenOtezla | $322 | $114,76224 claims |
| AbbVieRinvoq | $1,970 | $69,87211 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $769 | $33,29935 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $587 | $26,42532 claims |
| Almirall LLCKlisyri | $226 | $16,87415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 dermatology providers in South Carolina.
Other dermatology in Myrtle Beach
- Misty PolstonMyrtle Beach$16K
- Michael CentilliMyrtle Beach$10K
- Mary GloverMyrtle Beach$10K
- Cheryl ZeidmanMyrtle Beach$9K
- Christopher SkvarkaMyrtle Beach$9K
- Lucia GriffithMyrtle Beach$8K
- Todd SchlesingerCharleston$6.4M
- Matthew MillerGreenville$2.8M
- Marshall ShulerGreenville$2.6M
- Rebecca SmithFort Mill$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.